Zacks: Brokerages Anticipate Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) to Post -$0.31 Earnings Per Share
Wall Street brokerages predict that Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will announce ($0.31) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings. Xeris Pharmaceuticals posted earnings per share of ($0.89) during the same quarter last year, which suggests a positive year-over-year growth rate of 65.2%. The company is scheduled to report its next quarterly earnings report on Thursday, May 6th.
On average, analysts expect that Xeris Pharmaceuticals will report full year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.19) to ($1.00). For the next year, analysts expect that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($0.80) to ($0.69). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last released its earnings results on Monday, March 8th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $7.09 million during the quarter, compared to analyst estimates of $9.19 million. Xeris Pharmaceuticals had a negative net margin of 2,037.97% and a negative return on equity of 435.27%.
Shares of NASDAQ XERS traded down $0.11 during mid-day trading on Tuesday, reaching $3.59. 2,457,153 shares of the company’s stock were exchanged, compared to its average volume of 2,479,589. The firm has a market capitalization of $214.56 million, a price-to-earnings ratio of -0.90 and a beta of 2.22. The company has a current ratio of 6.86, a quick ratio of 6.65 and a debt-to-equity ratio of 4.49. The business has a fifty day simple moving average of $4.19 and a 200 day simple moving average of $4.99. Xeris Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $7.94.
In related news, insider Steven Prestrelski sold 10,000 shares of Xeris Pharmaceuticals stock in a transaction that occurred on Monday, April 12th. The stock was sold at an average price of $4.07, for a total value of $40,700.00. Following the sale, the insider now owns 496,824 shares of the company’s stock, valued at approximately $2,022,073.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.12% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in XERS. Marshall Wace LLP acquired a new stake in Xeris Pharmaceuticals in the 1st quarter valued at approximately $245,000. Marshall Wace North America L.P. acquired a new stake in Xeris Pharmaceuticals in the 1st quarter valued at approximately $71,000. FMR LLC raised its position in Xeris Pharmaceuticals by 29.9% in the 1st quarter. FMR LLC now owns 2,963,018 shares of the company’s stock valued at $29,749,000 after buying an additional 682,050 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Xeris Pharmaceuticals by 16.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 107,496 shares of the company’s stock valued at $638,000 after buying an additional 14,950 shares during the last quarter. Finally, Miracle Mile Advisors LLC grew its stake in Xeris Pharmaceuticals by 32.1% in the fourth quarter. Miracle Mile Advisors LLC now owns 119,300 shares of the company’s stock valued at $587,000 after purchasing an additional 29,000 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Recommended Story: G-20
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.